ZYMETX WILL APPLY GRANTS TO COMMERCIALIZE VIRAL DIAGNOSTICS.
The National Institute of Allergy and Infectious Disease has awarded ZymeTx a Phase I Small Business Innovative Research (SBIR) grant in the amount of $99,660 to fund development of a therapeutic treatment for Respiratory Syncytial Virus (RSV). RSV causes severe respiratory infections in infants and children and is the most common cause of bronchiolitis and pneumonia.
ZymeTx will use a three-year $213,280 grant from the Oklahoma Center for the Advancement of Science and Technology (OCAST) to fund additional commercial development of a newer, novel platform technology for rapid and sensitive detection of influenza and other viruses.
"Grants from these two distinguished organizations reflect a high level of confidence in the scientific expertise at ZymeTx," stated Proulx. "Furthermore, it further validates the science being pursued by ZymeTx scientists within the competitive worldwide academic and industrial communities. These scientists have revolutionized influenza disease management by successfully bringing to market the world's first rapid point-of-care flu diagnostic test, ZstatFlu(R)."
"Our influenza and RSV research programs have targeted two significant causes of morbidity and mortality from respiratory viral disease," stated Dr. Craig Shimasaki, Vice President of R&D and Operations at ZymeTx, Inc. "Funding the development of a more sensitive viral diagnostic platform technology represents an important step toward the eventual introduction of the next-generation viral diagnostic. A new therapeutic for the treatment of RSV will further strengthen our position as a viral disease management company."
The SBIR grants are awarded according to a rigorous scientific peer review process. Phase I funding maximum is $100,000 for six months. Successful programs become eligible to apply for Phase II funding of $1,000,000 for continued commercial development. The U.S. government stimulates economic development of technologies that are innovative and worthy of continuing through SBIR grants, while the company retains the worldwide patent rights to any invention developed with federal government support.
OCAST is a state agency that appropriates funding for new technology in Oklahoma through a similar scientific review process. Oklahoma's Economic Development Act of 1987 formed OCAST and has funded innovative research in the state with over $100 million.
ZymeTx, Inc., is an emerging biotechnology company engaged in the development of unique products for the diagnosis and treatment of viral disease, viral management and disease surveillance. The company developed ZstatFlu, the world's first rapid point-of-care test capable of detecting both Influenza A and B, and the National Flu Surveillance Network (NFSN), a network of surveillance sites located across the country with physicians using ZstatFlu to track influenza in their communities and practices. ZstatFlu and the National Flu Surveillance Network are trademarks of ZymeTx, Inc.
For more information, call 405/271-1314 or visit www.zymetx.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 1, 2000|
|Previous Article:||PPGX LAUNCHES GENETRIALS BIOINFORMATICS PLATFORM.|
|Next Article:||THERMOGEN AWARDED PHASE I SBIR GRANT TO DEVELOP NEW AMIDASES.|